CELZ-201-DDT

PreclinicalSmall molecule

CCreative Medical Technology Holdings Inc

CELZ-201-DDT is one of 42 small molecule programs targeting Back pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Back PainActive, not recruiting

Back PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

87 competitors in Back Pain

#DrugCompanyPhaseTrials

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

2 2

Celebrex

PPhiladelphia Eye Associates

Approved

—3

Vivarin

HHikma Pharmaceuticals LLC

Approved

—4

Buprenorphine/naloxone

Astellas

Approved

1 5

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 6

Suboxone

IIndivior Inc.

Phase 3

1 7

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 3

1 8

Botox

AbbVie

Phase 3

1 9

Pelubiprofen

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 10

Standard Medical Care

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Back Pain

NCT06053242

Clinical

Trials by Indication[1]

Back pain2 trials

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Recruiting·CCreative Medical Technology Holdings Inc·Phase 1/2·NCT06053242·45 enrolled

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Available·CCreative Medical Technology Holdings Inc··NCT07137559

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CELZ-201-DDT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CELZ-201-DDT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CELZ-201-DDT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Creative Medical Technology Holdings Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCreative Medical Technology Holdings Inc

CELZ-201-DDT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Back pain2 trials

References

Drug Info

Quick Facts

Related News